BAY 439695

Drug Profile

BAY 439695

Latest Information Update: 06 Oct 2006

Price : $50

At a glance

  • Originator Bayer
  • Class Antiretrovirals
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 06 Oct 2006 Discontinued - Phase-I for Cytomegalovirus infections treatment in USA (PO)
  • 15 Oct 2001 A study has been added to the Viral infections antimicrobial activity, drug interactions and pharmacodynamics sections
  • 21 Feb 2000 Phase-I clinical trials for Cytomegalovirus infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top